BERLIN — In June, Amgen reported that an experimental drug had hit the main goal of a gastric cancer study, improving overall survival in “a statistically significant and clinically meaningful” way.

From STAT’s Adam Feuerstein: Let’s start with Replimune, which said this morning the Food and Drug Administration will review ...

At a major cancer conference, Merck rolled out some showstoppers — data on drugs on which its business future may depend.

Patients with an aggressive form of breast cancer will likely have new treatment options after AstraZeneca and Gilead ...

AI tools designed to make health care more efficient are ubiquitous, though many remain piecemeal and siloed, as researchers ...

Noubar Afeyan tells the STAT Summit that political moves to replace facts with opinions won't stop with mRNA vaccines. "It’s ...

Mark Sendak was getting tired of seeing the toil of so many colleagues go to waste. At Duke University, he was part of a team ...

Gestational surrogacy faces serious threats from a powerful alliance that includes religious groups, MAHA supporters, and ...

Safeguarding biodiversity is not simply an environmental concern but a foundational element of preventive and clinical care.

AstraZeneca and Gilead both reported successful trials in a hard-to-treat form of breast cancer, sparking a debate about ...

In a case that was billed as profits versus patients, India’s Supreme Court dismissed a petition in which Roche sought to ...

A new study suggests that these vaccines might boost the effects of immunotherapy drugs, perhaps by alerting the immune ...